Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluation of Memory Skills in Patients Receiving Radiation Therapy for Brain Metastases
This study is ongoing, but not recruiting participants.
Study NCT00007007   Information provided by National Cancer Institute (NCI)
First Received: December 6, 2000   Last Updated: August 29, 2009   History of Changes

December 6, 2000
August 29, 2009
November 2000
 
 
 
Complete list of historical versions of study NCT00007007 on ClinicalTrials.gov Archive Site
 
 
 
Evaluation of Memory Skills in Patients Receiving Radiation Therapy for Brain Metastases
A Feasibility Study of Neurocognitive Evaluation in Patients Treated for Brain Metastases

RATIONALE: Assessment of patients undergoing radiation therapy may help to determine the effects of the treatment and may help improve cancer treatment.

PURPOSE: This clinical trial is studying the memory skills in patients receiving radiation therapy for brain metastases.

OBJECTIVES: I. Determine the feasibility of performing a test battery consisting of five neurocognitive measures and a quality of life instrument following radiotherapy in patients with brain metastases.

OUTLINE: Patients undergo radiotherapy 5 days a week for 3 weeks. Quality of life and neurocognitive function is assessed before study, at completion of radiotherapy, and at 1 month after completion of radiotherapy. Patients are followed at 1 month.

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study over 5 months.

 
Interventional
Other
  • Cognitive/Functional Effects
  • Metastatic Cancer
  • Radiation Toxicity
  • Procedure: management of therapy complications
  • Procedure: quality-of-life assessment
 
Regine WF, Schmitt FA, Scott CB, Dearth C, Patchell RA, Nichols RC Jr, Gore EM, Franklin RL 3rd, Suh JH, Mehta MP. Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1346-52.

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Active, not recruiting
 
 
 

DISEASE CHARACTERISTICS: Histologically proven primary malignancy No primary site of hematopoietic origin (leukemia) No leptomeningeal involvement At least 1 measurable brain metastasis by CT or MRI

PATIENT CHARACTERISTICS: Age: Not specified Performance status: Zubrod 0-1 Life expectancy: At least 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not pregnant or nursing Fertile patients must use effective contraception Neurological function classification 0-2 No major medical illnesses or psychiatric impairments that would preclude study

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to the brain Surgery: Not specified

Both
 
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT00007007
 
CDR0000068366, RTOG-BR-0018, RTOG-DEV-1053
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
Study Chair: William F. Regine, MD Lucille P. Markey Cancer Center at University of Kentucky
National Cancer Institute (NCI)
November 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP